EB 003 - Enveric Biosciences
Alternative Names: EB-003 - Enveric BiosciencesLatest Information Update: 22 Nov 2024
Price :
$50 *
At a glance
- Originator Enveric Biosciences
- Class Antidepressants; Anxiolytics; Small molecules
- Mechanism of Action 5-HT1A serotonin receptor modulators; Serotonin 5-HT2A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Anxiety disorders; Depressive disorders
Most Recent Events
- 14 Nov 2024 Enveric Biosciences announces intention to submit an Investigational New Drug Application (IND) for Anxiety disorders and Depressive disorders in the second half of 2025
- 17 Oct 2024 Pharmacodynamics and adverse events data from a preclinical studies in Anxiety disorders and Depressive disorders released by Enveric Biosciences
- 25 Jul 2024 Preclinical trials in Anxiety disorders in Italy (PO) prior to July 2024